Clinical Trial

Hepatoprotective Measures for Children at High Risk of NAFLD

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated April 9, 2025 (before its estimated May 2025 completion). Its status may not reflect the trial's current state.
Summary
Non Alcoholic Fatty Liver Disease (NAFLD) is a spectrum of disease, ranging from simple fatty deposition (steatosis) to inflammation (steatohepatitis), fibrosis, cirrhosis, and end-stage liver failure. In childhood, it may be associated with a metabolic syndrome or with obesity, or even in normal children. Liver biopsy has always been the gold standard method for diagnosing and staging NAFLD. However, the urge of non-invasive biomarkers or imaging techniques has been recommended. This study will evaluate the use of the LIVERFASt biomarkers for early detection and staging of NAFLD.
Trial Details
NCT Number NCT06918080
Lead Sponsor Ain Shams University
Conditions Non Alcoholic Fatty Liver Diseases (NAFLD), Obesity and Overweight, Acute Lymphoblastic Leukemia
Enrollment 200 participants
Start Date 2023-11-19
Primary Completion 2025-05 (estimated)
Study Completion 2025-07 (estimated)
Updated on ClinicalTrials.gov 2025-04-09